Jacob Falck Hansen appointed as Chief Executive Officer of Vesper Bio

Copenhagen, Denmark, 01 July 2025 – Vesper Bio ApS (“Vesper” or “the Company”), a clinical stage biotech developing an oral therapy for frontotemporal dementia, today announces the appointment of Jacob Falck Hansen as Chief Executive Officer (CEO). Jacob Falck Hansen brings more than 15 years of leadership experience from the pharmaceutical and biotech industry. He […]

Challenge accepted: New funding for ambitious projects within biomanufacturing, cardiometabolic diseases, and artificial intelligence

The 2025 Novo Nordisk Foundation Challenge Programme awards DKK 479 million to nine innovative projects that advance health and sustainability through cooperation between researchers from all over the globe, including Denmark, Sweden, The Netherlands, Belgium, Germany, Australia, and the USA. Read more…

STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer

26 June 2025, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced the appointment of accomplished cancer biologist Dr. Eric Martin, PhD, as Chief Development Officer (CDO). Dr. Martin has over 20 years of experience in oncology research and drug development spanning both […]

Curve Therapeutics Co-Founder and CSO Professor Ali Tavassoli awarded the Royal Society of Chemistry’s Interdisciplinary Prize

Awarded in recognition of excellence in research and innovation and contribution to scientific progress Reflects the revolutionary potential of Curve’s gene-encoded Microcycle® platform to unlock the therapeutic potential of intracellular targets Southampton, UK, 25 June 2025 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company building a pipeline of innovative cyclic peptide and […]

New Danish research centre to make designed proteins with vast potential

Designed proteins are anticipated to have groundbreaking impact on a range of issues from treating disease to tackling environmental problems. With a DKK 700 million grant from the Novo Nordisk Foundation and headed by Professor Dek Woolfson, a new Center for Protein Design (CPD) at the University of Copenhagen has ambitions to match this potential. […]